PARP Inhibitors in Oncology

PARP Inhibitors in Oncology

Summary

Poly (ADP-ribose) polymerase (PARP) enzymes play important roles in the repair of single-strand breaks (SSBs) in DNA. SSBs occur from environmental agents, spontaneous DNA bond disruption, or normal DNA metabolism. PARP1 binds to DNA following SSB and recruits other enzymes to repair the DNA damage.

Since hitting the market in 2015, drugs that target poly (ADP-ribose) polymerase (PARP) have transformed the clinical management of cancers harboring BRCA-mutations. There are three approved PARP inhibitors and five pipeline therapies in Phase II and Phase III clinical development. While the majority of trials are focused on ovarian and breast cancer, makers of pipeline therapies are seeing a saturated market and turning towards prostate, pancreatic, and other cancers.

As more PARP inhibitors have been commercialized, drug developers are turning their attention towards broadening drug labels and exploring combination strategies. With greater emphasis being placed on combinations with PD-1/PD-L1 inhibitors in breast cancer, as well as combinations with chemotherapy in ovarian, breast, prostate, and other cancers.

The report "PARP Inhibitors in Oncology", covers the management of PARP inhibitors in the US, Europe, and Asia, focusing on efficacy and safety comparisons for approved products, current and future indications, and research and development strategies.

Companies Mentioned: AbbVie, AstraZeneca, BeiGene, Clovis Oncology, Jiangsu Hengrui Medicine Co., Merck, Nerviano Medical Sciences, Oncology Venture, Pfizer, Sanofi, SyntheX, Tesaro

Scope

This report combines key opinion leader insight with in-house analyst expertise and research to provide an insight-rich look at PARP inhibitors in the US, Europe, and Asia.

Components of the report include:

• Overview of PARP Inhibitors in Oncology: Background, mechanism of action, and clinical development of PARP inhibitors.


• Epidemiology Analysis: Which current and future disease spaces are relevant to PARP inhibitors.


• Marketed PARP Inhibitors: How the currently approved PARP inhibitors compare.


• Pipeline Assessment in the 8MM: What are the pipeline PARP inhibitor products in development in oncology.


• Key Players: What companies are developing PARP inhibitors in oncology.


• Research and Development Strategies: How are PARP inhibitor clinical trials being designed, and what combination strategies are being explored in the US, Europe, and Asia.


• Pricing, Reimbursement, and Regulatory Strategies: What current and future challenges face PARP inhibitors from a payer’s perspective.

Reasons to buy

• Develop business strategies by understanding the trends shaping and driving the PARP inhibitor market in the US, Europe, and Asia.


• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the portfolios of various competitors.


• Identify areas of unmet need within the PARP inhibitor market to help drive research and development towards future market opportunities.


• Gain insights to help plan and design your clinical trials.


• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.


• Identify key pricing and reimbursement strategies.